Citation
Bickeböller, H, et al. "Apolipoprotein E and Alzheimer Disease: Genotype-specific Risks By Age and Sex." American Journal of Human Genetics, vol. 60, no. 2, 1997, pp. 439-46.
Bickeböller H, Campion D, Brice A, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet. 1997;60(2):439-46.
Bickeböller, H., Campion, D., Brice, A., Amouyel, P., Hannequin, D., Didierjean, O., Penet, C., Martin, C., Pérez-Tur, J., Michon, A., Dubois, B., Ledoze, F., Thomas-Anterion, C., Pasquier, F., Puel, M., Demonet, J. F., Moreaud, O., Babron, M. C., Meulien, D., ... Clerget-Darpoux, F. (1997). Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. American Journal of Human Genetics, 60(2), 439-46.
Bickeböller H, et al. Apolipoprotein E and Alzheimer Disease: Genotype-specific Risks By Age and Sex. Am J Hum Genet. 1997;60(2):439-46. PubMed PMID: 9012418.
TY - JOUR
T1 - Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.
AU - Bickeböller,H,
AU - Campion,D,
AU - Brice,A,
AU - Amouyel,P,
AU - Hannequin,D,
AU - Didierjean,O,
AU - Penet,C,
AU - Martin,C,
AU - Pérez-Tur,J,
AU - Michon,A,
AU - Dubois,B,
AU - Ledoze,F,
AU - Thomas-Anterion,C,
AU - Pasquier,F,
AU - Puel,M,
AU - Demonet,J F,
AU - Moreaud,O,
AU - Babron,M C,
AU - Meulien,D,
AU - Guez,D,
AU - Chartier-Harlin,M C,
AU - Frebourg,T,
AU - Agid,Y,
AU - Martinez,M,
AU - Clerget-Darpoux,F,
PY - 1997/2/1/pubmed
PY - 1997/2/1/medline
PY - 1997/2/1/entrez
SP - 439
EP - 46
JF - American journal of human genetics
JO - Am J Hum Genet
VL - 60
IS - 2
N2 - The distribution of apolipoprotein E (APOE) genotypes as a function of age and sex has been examined in a French population of 417 Alzheimer disease (AD) patients and 1,030 control subjects. When compared to the APOE epsilon3 allele, an increased risk associated with the APOE epsilon4 allele (odds ratio [OR] [epsilon4] = 2.7 with 95% confidence interval [CI] = 2.0-3.6; P < .001) and a protective effect of the APOE epsilon2 allele (OR[epsilon2] = 0.5 with 95% CI = 0.3-0.98; P = .012) were retrieved. An effect of the epsilon4 allele dosage on susceptibility was confirmed (OR[epsilon4/epsilon4] vs. the epsilon3/epsilon3 genotype = 11.2 [95% CI = 4.0-31.6]; OR[epsilon3/epsilon4] vs. the epsilon3/epsilon3 genotype = 2.2 [95% CI = 1.5-3.5]). The frequency of the epsilon4 allele was lower in male cases than in female cases, but, since a similar difference was found in controls, this does not lead to a difference in OR between sex. ORs for the epsilon4 allele versus the epsilon3 allele, OR(epsilon4), were not equal in all age classes: OR(epsilon4) in the extreme groups with onset at < 60 years or > 79 years were significantly lower than those from the age groups 60-79 years. In epsilon3/epsilon4 individuals, sex-specific lifetime risk estimates by age 85 years (i.e., sex-specific penetrances by age 85 years) were 0.14 (95% CI 0.04-0.30) for men and 0.17 (95% CI 0.09-0.28) for women.
SN - 0002-9297
UR - https://www.unboundmedicine.com/medline/citation/9012418/Apolipoprotein_E_and_Alzheimer_disease:_genotype_specific_risks_by_age_and_sex_
DB - PRIME
DP - Unbound Medicine
ER -